Inclusion Criteria

Inclusion

- Patients must have pathologically documented T-cell lymphoma belonging to one of the
following WHO entities: Peripheral T-cell lymphoma, not otherwise specified
(PTCL-NOS); Mycosis Fungoides and Sezary Syndrome (MF-SS); Angioimmunoblastic T-cell
lymphoma (AITL); CD30-positive Anaplastic Large Cell Lymphoma (ALCL), systemic;
T/NK-cell lymphoma, extranodal, nasal and nasal type; Hepatosplenic T-cell lymphoma,
gamma/delta or alpha/beta; Enteropathy-associated T-cell lymphoma (EATL); Adult
T-cell Leukemia/Lymphoma (ATLL); Subcutaneous panniculitis-like T-cell lymphoma
(SCPTCL); Blastic T/NK-cell lymphoma/leukemia (CD4+CD56+ Hematodermic Tumor);
T/NK-cell post-transplant lymphoproliferative disorders (PTLD); Large Granular
Lymphocyte (LGL) Leukemia; T-cell Prolymphocytic Leukemia (T-PLL)

- Patients must have relapsed or refractory TCL

- Patients must have failed at least one prior systemic therapy

- Life expectancy must be greater than 3 months

- Eastern Cooperative Oncology Group (ECOG) performance status =< 2

- Patients must have adequate organ function as defined below:

- Total bilirubin < 1.5 x upper limit of normal (ULN)

- AST(SGOT) < 2.0 x ULN

- ALT(SGPT) < 2.0 x ULN

- Serum creatinine < 1.5 ULN

- New York Heart Association Congestive Heart Failure (NYHA CHF) Class II or better

- Platelet count >= 75,000/mm^3 (unless due to disease) within 14 days before
enrollment

- Absolute neutrophil count of >= 1,500/mm^3 within 14 days before enrollment

- Women of childbearing potential must have a negative serum pregnancy test prior to
azacitidine treatment; women of child-bearing potential and men must agree to use
adequate contraception (hormonal or barrier method of birth control; abstinence)
prior to study entry and for the duration of study participation; if the patient does
not agree, the patient is not eligible; women must agree to not get pregnant for the
duration of the study; should a woman become pregnant or suspect she is pregnant
while participating in this study, she should inform the PI or the Study Nurse
immediately

- Ability to understand and willingness to sign the written informed consent document
before performance of any study-related procedure not part of normal medical care,
with the understanding that consent may be withdrawn by the subject at any time
without prejudice to future medical care

- Male subject agrees to use an acceptable method for contraception for the duration of
the study

Exclusion

- Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study

- Patients receiving any other investigational agents or patients who have received
other investigational agents within 14 days of enrollment

- Patients with active central nervous system (CNS) malignancy

- Patients with history of allergic reactions attributed to compounds of similar
chemical or biologic composition to Azacitidine or VELCADE (BORTEZOMIB) that are not
easily managed; patients with hypersensitivity to VELCADE (BORTEZOMIB), boron, or
mannitol

- Patients must not have previously received Azacitidine or VELCADE (BORTEZOMIB) for
any disease

- Uncontrolled intercurrent illness including, but not limited to, symptomatic
congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, or
psychiatric illness/social situations that would limit compliance with study
requirements; as infection is a common feature of TCL, patients with active infection
are permitted to enroll provided that the infection is under control; myocardial
infarction within 6 months prior to enrollment or has NYHA Class III or IV heart
failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or
electrocardiographic evidence of acute ischemia or active conduction system
abnormalities; prior to study entry, any ECG abnormality at screening has to be
documented by the investigator as not medically relevant

- Pregnant women or women who are breastfeeding are excluded from this study;
confirmation that the subject is not pregnant must be established by a negative serum
beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during
screening; pregnancy testing is not required for post-menopausal or surgically
sterilized women

- HIV-positive patients are ineligible; all patients will be screened for HIV

- Patients with pre-existing Grade 2 or higher neuropathy within 14 days before
enrollment or other serious neurologic toxicity that would significantly increase
risk of complications from VELCADE (BORTEZOMIB) therapy are excluded

- Patients with active, advanced malignant solid tumors are excluded

- Patients with serious medical or psychiatric illness likely to interfere with
participation in this clinical study

- Diagnosed or treated for another malignancy within 3 years of enrollment, with the
exception of complete resection of basal cell carcinoma or squamous cell carcinoma of
the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy